Momelotinib Hits the Mark for Deadly Bone Marrow Cancer

The investigational drug has shown benefits in myelofibrosis in a new phase 3 trial with a new sponsor, which plans to apply for FDA approval.

Related Keywords

Boston ,Massachusetts ,United States ,American ,Jolla Pharma ,Ruben Mesa ,Gabriela Hobbs ,Genentech Incyte ,Mays Cancer Center ,American Society Of Clinical Oncology ,Constellation Pharmaceuticals ,Drug Administration ,Harvard Medical School ,Sierra Oncology ,American Society ,Manderson Cancer ,Constellation Pharmaceutical ,Myelofibrosis ,Anemia ,Hematology ,Financing ,Transfusion ,